Monthly Archives: December 2017

The Klein Law Firm Reminds Shareholders of a Class Action on Behalf of Array Biopharma Inc. Shareholders and a Lead Plaintiff Deadline of January 22, 2018 (ARRY)

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The Klein Law Firm notifies shareholders that a class action complaint has been filed on behalf of shareholders of Array Biopharma Inc. (NASDAQ: ARRY) who purchased shares between December 16, 2015 and March 17, 2017. The action, which was filed in the United States District Court for the District of Colorado, alleges that the Company violated federal securities laws.

In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma; (2) Array was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutual melanoma; and (3) as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times.

Shareholders have until January 22, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/array-biopharma-inc-arry?wire=2.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 484979

TVTY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Tivity Health, Inc. and a Lead Plaintiff Deadline of January 19, 2018

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of investors who purchased Tivity Health, Inc. (NASDAQ: TVTY) between February 24, 2017 and November 3, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sbm/tivity-health-inc?wire=2. There is no cost or obligation to you.

According to the complaint, throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Tivity Health was aware that its customer United Healthcare, Inc. planned to expand its fitness benefit to seniors, (ii) the aforementioned expansion would represent direct competition to Tivity Health’s core program SilverSneaker, and (iii) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Tivity Health’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Tivity you have until January 19, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/tivity-health-inc?wire=2.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 484978

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Gener8 Maritime, Inc – GNRT

BALA CYNWYD, PA / ACCESSWIRE / December 27, 2017 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Gener8 Maritime, Inc. (“Gener8” or “the Company”) (NYSE: GNRT) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Euronav.

Click here to learn more http://www.brodskysmith.com/cases/gener8-maritime-inc-nyse-gnrt/, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Gener8 shareholders will receive only 0.7272 of a share of Euronav for each share of Gener8 stock they own. The investigation concerns whether the Board of Gener8 breached their fiduciary duties to shareholders and whether Euronav is underpaying for the Company. The transaction may undervalue the Company as shares of Gener8 stock have traded at $13.72 per share.

If you own shares of Gener8 stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 484985

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. – SCMP

BALA CYNWYD, PA / ACCESSWIRE / December 27, 2017 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Sucampo Pharmaceuticals, Inc. (“Sucampo” or “the Company”) (NASDAQ: SCMP) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Mallinckrodt plc (“Mallinckrodt”).

Click here to learn more http://www.brodskysmith.com/cases/sucampo-pharmaceuticals-inc-nasdaq-scmp/, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Sucampo shareholders will receive only $18.00 in cash for each share of Sucampo stock they own. The investigation concerns whether the Board of Sucampo breached their fiduciary duties to shareholders and whether Mallinckrodt is underpaying for the Company. The transaction may undervalue the Company and would result in a loss for many Sucampo shareholders. For example, shares of Sucampo stock have traded at $26.86 per share and an analyst has set a price target for Sucampo stock at $43.00 per share.

If you own shares of Sucampo stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/sucampo-pharmaceuticals-inc-nasdaq-scmp/, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 484982

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 – ACOR

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Acorda Therapeutics, Inc. (“Acorda”) (NASDAQ: ACOR) between April 18, 2016 and November 14, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information, go to:

http://www.zlk.com/plsra-c/acorda-therapeutics-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the drug treatment tozadenant entailed significant undisclosed safety risks; (ii) accordingly, the Company had overstated tozadenant’s approval prospects and commercial viability; (iii) the Company had likewise overstated the benefits of the Biotie Acquisition; and (iv) as a result of the foregoing, Acorda’s shares traded at artificially inflated prices during the Class Period.

On November 15, 2017, Acorda revealed it had ceased enrolling new patients in its Phase 3 trial of its Parkinson’s treatment due to patient deaths.

If you suffered a loss in Acorda, you have until January 17, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 484977

Hemp Naturals Inc. is Excited to Announce our Nighttime Snack, “Twilight Bars”

SUNNY ISLES BEACH, FL / ACCESSWIRE / December 27, 2017 / Hemp Naturals, Inc. (OTC PINK: HPMM), a fully reporting consumer goods company specializing in hemp- infused food and beverage products, announced today that it will enter the $50 billion nighttime snack industry.

Hemp naturals inc is excited to announce our revolutionary new “Twilight Bars”. The bars are a perfect fit with our CBD infused product line. Twilight Bars will be infused with natural nighttime dietary supplements to help with a better sleep, as well as satisfying any nighttime cravings. They are also organic, kosher, vegan, and free of GMOs, gluten, soy, dairy, chemicals, preservatives, and added oils or fats, providing a ‘clean’ new plant-based bar option for consumers who wish to have a better sleep and not feel guilty about it.

About Hemp Naturals, Inc.

Hemp Naturals, Inc. is an early stage company in the research, development, and marketing of hemp and non-hemp-based products. For more information on Hemp Naturals Inc., please visit: http://hempofnaturals.com. Hemp Naturals plans to make a wide variety of products out of hemp-based and non-hemp based materials along with supplementary goods. This includes, but is not limited to, our Hemp Naturals Rolling Paper, and Five flavors of Ice Tea, which will be going into production as early as next month. Hemp Naturals plans to fill the growing need and demand for hemp and non- hemp-based products within the United States through aggressive marketing and by ensuring that a number of major retailers stock products created by Hemp Naturals. The company plans to follow all Federal regulations and statutes pertinent to the sale of hemp-based goods.

Cautionary Language Concerning Forward-Looking Statements:

This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for Hemp Naturals products, the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in Hemp Naturals filings with the United States Securities and Exchange Commission. Examples of such forward-looking statements in this release include statements regarding future sales, costs and market acceptance of products as well as regulatory actions at the State or Federal level. For a more detailed description of the risk factors and uncertainties affecting Hemp Naturals please refer to the Company’s Securities and Exchange Commission filings, which are available at www.sec.gov. Hemp Naturals undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

Investor Relations:
Joshua Dezer
joshuadezermedia@gmail.com
(646) 370-9698

SOURCE: Hemp Naturals, Inc.

ReleaseID: 484983

ACT NOW: Monteverde & Associates PC Announces An Investigation Of General Communication, Inc. – GNCMA

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating General Communication, Inc. (“General Communication” or the “Company”) (NASDAQ: GNCMA) relating to the sale of the Company to affiliates of Liberty Interactive Corporation (QVCA, QVCB, LVNTA, LVNTB) As a result of the merger General Communication shareholders are only anticipated to receive $32.50 in cash for each share of General Communication.

Click here for more information: http://monteverdelaw.com/investigations/m-a/. It is free and there is no cost or obligation to you.

The investigation focuses on whether General Communication and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company’s by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company and 3) failing to disclose all material financial information in connection with the shareholder meeting on February 2, 2018.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017 Top Rated Lawyer.

If you own common stock in General Communication and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2017 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC

ReleaseID: 484976

ACT NOW: Monteverde & Associates PC Announces An Investigation Of General Cable Corporation – BGC

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating General Cable Corporation (“General Cable” or the “Company”) (NYSE: BGC) relating to the sale of the Company to Prysmain Group. As a result of the merger, General Cable shareholders are only anticipated to receive $30.00 in cash in exchange for each share of General Cable.

Click here for more information: http://monteverdelaw.com/investigations/m-a/. It is free and there is no cost or obligation to you.

The investigation focuses on whether General Cable and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company’s stockholders by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company and 3) failing to disclose all material financial information in connection with the upcoming shareholder meeting.

Monteverde & Associates PC is a boutique class action securities and consumer litigation law firm that has recovered millions of dollars and is committed to protecting shareholders and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013 and 2017, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017 Top Rated Lawyer.

If you own common stock in General Cable and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:

Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2017 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE: Monteverde & Associates PC

ReleaseID: 484975

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Omega Healthcare, Inc. Investors of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2018 – OHI

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Omega Healthcare Investors, Inc. (“Omega”) (NYSE: OHI) between February 8, 2017 and October 31, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information, go to:

http://www.zlk.com/plsra-c/omega-healthcare-investors-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) financial and operating results of certain of the Company’s operators were deteriorating; (2) as a result, certain of the Company’s operators were experiencing worsening liquidity issues that were significantly impacting the operators’ ability to make timely rent payments; (3) as a result, certain of the Company’s direct financing leases were impaired and certain receivables were uncollectible; and (4) that, as a result of the foregoing, Defendants’ statements about Omega’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

If you suffered a loss in Omega, you have until January 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 484974

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 – NOVN

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Novan, Inc. (“Novan”) (NASDAQ: NOVN) (1) pursuant and/or traceable to Novan’s IPO on or about September 26, 2016 or (2) between September 26, 2016 and August 1, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information, go to:

http://www.zlk.com/pslra-sbm/novan-inc?wire=1

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that the Company made materially false and/or misleading statements in its Registration Statement and Prospectus for the IPO, and made false statements throughout the class period. In particular, among other allegations, the complaint alleges that the Company repeatedly falsely stated that two Phase 3 clinical trials for the treatment SB204 were identical and omitted specific facts as to why the two critical trials were, in fact, not identical; as a result of these false statements, the Company’s outlook and expected financial performance were not accurately represented.

If you suffered a loss in Novan, you have until January 2, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll-Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 484973